Special Issue

Strategies of Viral Vectors for Vaccine Development—2nd Edition

Message from the Guest Editor

Viral vectors have been studied as innovative tools in the field of medicine. With advancements in technology, these vectors are becoming increasingly sophisticated, leading to a broader range of applications. They can be utilized to deliver therapeutic drugs, facilitate the expression of foreign proteins, and specifically target and destroy cancer cells, thereby enhancing treatment efficacy and effectiveness. This Special Issue will center on the development and optimization of viral vectors derived from various sources, including animal, plant, and bacterial viruses. Our goal is to leverage these vectors to create safe, effective, and cost-efficient vaccines. We eagerly anticipate your valuable contributions to this exciting area of research.

Guest Editor

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Deadline for manuscript submissions

30 September 2026



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/254586

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

